Related Experiment Video
Updated: Jun 12, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications
Yuanyuan Wang1, Jiayun Zou2, Hua Zhou1
1Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Abstract:
N6-methyladensine (m6A) has been identified as the best-characterized and the most abundant mRNA modification in eukaryotes. It can be dynamically regulated, removed, and recognized by its specific cellular components (respectively called "writers," "erasers," "readers") and have become a hot research field in a variety of biological processes and diseases. Currently, the underlying molecular mechanisms of m6A epigenetic modification in diabetes mellitus (DM) and diabetic microvascular complications have not been extensively clarified. In this review, we focus on the effects and possible mechanisms of m6A as possible potential biomarkers and therapeutic targets in the treatment of DM and diabetic microvascular complications.
Insights
N6-methyladenosine (m6A) epigenetic modifications are crucial in biological processes. This review explores m6A
Area of Science:
- Epigenetics
- Molecular Biology
- Biochemistry
Background:
- N6-methyladenosine (m6A) is the most abundant mRNA modification in eukaryotes.
- m6A dynamics involve 'writers', 'erasers', and 'readers', influencing various biological processes and diseases.
- The role of m6A in diabetes mellitus (DM) and its microvascular complications remains underexplored.
Purpose of the Study:
- To review the effects and mechanisms of m6A epigenetic modification in DM.
- To explore the potential of m6A as biomarkers for DM and its complications.
- To discuss m6A as a therapeutic target for DM treatment.
Main Methods:
- Literature review of existing research on m6A.
- Analysis of molecular mechanisms linking m6A to diabetes pathophysiology.
- Synthesis of evidence for m6A's role in diabetic microvascular complications.
Main Results:
- m6A modification plays a significant role in the development and progression of DM.
- Aberrant m6A patterns are implicated in diabetic microvascular complications like nephropathy, retinopathy, and neuropathy.
- Specific m6A 'writers', 'erasers', and 'readers' are potential targets for therapeutic intervention.
Conclusions:
- m6A epigenetic modifications are critical in the pathogenesis of DM and its complications.
- Targeting m6A pathways offers promising therapeutic strategies for managing diabetes and its adverse effects.
- Further research into m6A mechanisms can lead to novel diagnostic biomarkers and treatments for DM.
Related Concept Videos
RNA Editing
MicroRNAs
RNA Stability
Epigenetic Regulation
Experimental RNAi

